foi
services
incorporated

Drugs Under Patent

A comprehensive guide to FDA-approved pharmaceuticals under patent and marketing exclusivity

1989 Edition

foi
services
incorporated

Drugs Under Patent

1989 Edition

Published by:
FOI Services, Inc.
12315 Wilkins Avenue
Rockville MD 20852-1877, U.S.A.

Phone: 301/881-0410
Fax: 301/881-0415

International Standard Book Number: 0-9622958-0-9

Printed in the United States of America

All information included in **Drugs Under Patent** was derived directly from FDA's computer tape of approved drug products. Therefore, the publisher of this book cannot accept responsibility for errors or omissions in the listings. This book should be regarded only as a guide to patent and exclusivity expirations; further verification of these data should be done before accepting this information as correct.

foi
services
incorporated

Drugs Under Patent

1989 Edition

Published by:
FOI Services, Inc.
12315 Wilkins Avenue
Rockville MD 20852-1877, U.S.A.

Phone: 301/881-0410
Fax: 301/881-0415

International Standard Book Number: 0-9622958-0-9

Printed in the United States of America

All information included in **Drugs Under Patent** was derived directly from FDA's computer tape of approved drug products. Therefore, the publisher of this book cannot accept responsibility for errors or omissions in the listings. This book should be regarded only as a guide to patent and exclusivity expirations; further verification of these data should be done before accepting this information as correct.

Introduction

On September 24, 1984, the Drug Price Competition and Patent Term Restoration Act was signed into law. Among other things, the Act determined which drugs qualify for periods of exclusivity (during which Abbreviated New Drug Applications for those drugs may either not be submitted or made effective), and provided a mechanism for extending the patent term of a drug which encountered delays during the review process.

Drugs Under Patent provides complete listings of pharmaceuticals affected by the 1984 Act, offering index points by company name, drug trade and generic names, expiration date, dosage form, exclusivity code, patent number and NDA number.

All data used to prepare **Drugs Under Patent** were obtained from the Food & Drug Administration's listing of approved drug products as of June 1989. Therefore, the publisher of this book cannot accept responsibility for errors or omissions in the listings. This book should be regarded only as a guide to patent and exclusivity expirations; further verification of these data should be done before accepting this information as correct.

Important Notice

This printing of **Drugs Under Patent - 1989 Edition** is a replacement for an earlier press run, which contained incorrect data.

If you have any copies of this book with a **blue cover**, please discard them, as they contain several incorrect patent and exclusivity dates.

Section 1 — Company Index

Section 1 lists drugs under patent alphabetically by company name. This is the main index in this book, and the only index containing all of the information for each product. Within each company, individual drugs are listed alphabetically by generic name. The company name has been standardized for each reference; if the company or product you are seeking does not appear, be sure to check the listing for the parent company. Company names that denote names of people are alphabetized by surname (e.g. Eli Lilly will be found under "L").

Please note that blank fields indicate that the data are not applicable or do not appear on FDA's master list of approved drug products.

Sample Record:

Ciba Pharmaceutical (1)

Chlorthalidone 25Mg; Metoprolol Tartrate 100Mg (2)
Lopressidone (3)
Capsule; Oral (4)
NDA No: N19451 (5) Approved: 12/31/87 (6)

(7) Patent Date: 12/21/93
(8) Exclusivity Date: 12/31/90
(9) Exclusivity Code: NC
(10) Patent Number: 3998790
(11) Discontinued:
(12) Withdrawn:

Key:

1 — Company Name
2 — Drug generic name and strength
3 — Drug trade name - if no trade name, then generic name repeated
4 — Dosage form and route
5 — NDA (FDA New Drug Application) number
6 — Date of NDA approval
7 — Date of patent expiration
8 — Date of exclusivity expiration
9 — Exclusivity code — see section 6 for a translation of these codes
10 — Patent number
11 — Date the manufacturer discontinued product marketing (if applicable)
12 — Date of withdrawal of FDA approval (if applicable)

Abbott Laboratories

1 Co.

Calcitriol 0.001Mg/Ml		Patent Date:	12/29/98
Calcijex		Exclusivity Date:	
Injection; Intravenous		Exclusivity Code:	
NDA No: 18874	Approved: 09/25/86	Patent Number:	4308264
Calcitriol 0.001Mg/Ml		Patent Date:	10/10/89
Calcijex		Exclusivity Date:	09/24/89
Injection; Intravenous		Exclusivity Code:	NDF
NDA No: 18874	Approved: 09/25/86	Patent Number:	3697559
Calcitriol 0.002Mg/Ml		Patent Date:	12/29/98
Calcijex		Exclusivity Date:	
Injection; Intravenous		Exclusivity Code:	
NDA No: 18874	Approved: 09/25/86	Patent Number:	4308264
Calcitriol 0.002Mg/Ml		Patent Date:	10/10/89
Calcijex		Exclusivity Date:	09/24/89
Injection; Intravenous		Exclusivity Code:	NDF
NDA No: 18874	Approved: 09/25/86	Patent Number:	3697559
Carteolol Hydrochloride 10Mg		Patent Date:	10/07/92
Cartrol		Exclusivity Date:	12/28/93
Tablet; Oral		Exclusivity Code:	NCE
NDA No: 19204	Approved: 12/28/88	Patent Number:	3910924
Carteolol Hydrochloride 2.5Mg		Patent Date:	10/07/92
Cartrol		Exclusivity Date:	12/28/93
Tablet; Oral		Exclusivity Code:	NCE
NDA No: 19204	Approved: 12/28/88	Patent Number:	3910924
Carteolol Hydrochloride 5Mg		Patent Date:	10/07/92
Cartrol		Exclusivity Date:	12/28/93
Tablet; Oral		Exclusivity Code:	NCE
NDA No: 19204	Approved: 12/28/88	Patent Number:	3910924
Etomidate 2Mg/Ml		Patent Date:	
Amidate		Exclusivity Date:	09/07/92
Injection; Intravenous		Exclusivity Code:	NCE
NDA No: 18227	Approved: 09/07/82	Patent Number:	
Leuprolide Acetate 7.5Mg/Vial		Patent Date:	
Lupron Depot		Exclusivity Date:	01/26/92
Injection; Intramuscular		Exclusivity Code:	NP
NDA No: 19732	Approved: 01/26/89	Patent Number:	

Leuprolide Acetate 7.5Mg/Vial		Patent Date:	01/25/96
Lupron Depot		Exclusivity Date:	04/09/90
Injection; Intramuscular		Exclusivity Code:	NCE
NDA No: 19732	Approved: 01/26/89	Patent Number:	4005063
Protirelin 0.5Mg/Ml		Patent Date:	07/17/90
Thypinone		Exclusivity Date:	
Injection; Intravenous		Exclusivity Code:	
NDA No: 17638	Approved: 11/05/76	Patent Number:	3746697
Terazosin Hydrochloride 10Mg		Patent Date:	02/17/00
Hytrin		Exclusivity Date:	08/07/92
Tablet; Oral		Exclusivity Code:	NCE
NDA No: 19057	Approved: 08/07/87	Patent Number:	4251532
Terazosin Hydrochloride 10Mg		Patent Date:	05/31/94
Hytrin		Exclusivity Date:	
Tablet; Oral		Exclusivity Code:	
NDA No: 19057	Approved: 08/07/87	Patent Number:	4026894
Terazosin Hydrochloride 10Mg		Patent Date:	09/05/95
Hytrin		Exclusivity Date:	
Tablet; Oral		Exclusivity Code:	
NDA No: 19057	Approved: 08/07/87	Patent Number:	4112097
Terazosin Hydrochloride 1Mg		Patent Date:	09/05/95
Hytrin		Exclusivity Date:	
Tablet; Oral		Exclusivity Code:	
NDA No: 19057	Approved: 08/07/87	Patent Number:	4112097
Terazosin Hydrochloride 1Mg		Patent Date:	02/17/00
Hytrin		Exclusivity Date:	08/07/92
Tablet; Oral		Exclusivity Code:	NCE
NDA No: 19057	Approved: 08/07/87	Patent Number:	4251532
Terazosin Hydrochloride 1Mg		Patent Date:	05/31/94
Hytrin		Exclusivity Date:	
Tablet; Oral		Exclusivity Code:	
NDA No: 19057	Approved: 08/07/87	Patent Number:	4026894
Terazosin Hydrochloride 2Mg		Patent Date:	05/31/94
Hytrin		Exclusivity Date:	
Tablet; Oral		Exclusivity Code:	
NDA No: 19057	Approved: 08/07/87	Patent Number:	4026894

1 Co.

Terazosin Hydrochloride 2Mg
Hytrin
Tablet; Oral
NDA No: 19057 Approved: 08/07/87

Patent Date: 09/05/95
Exclusivity Date:
Exclusivity Code:
Patent Number: 4112097

Terazosin Hydrochloride 2Mg
Hytrin
Tablet; Oral
NDA No: 19057 Approved: 08/07/87

Patent Date: 02/17/00
Exclusivity Date: 08/07/92
Exclusivity Code: NCE
Patent Number: 4251532

Terazosin Hydrochloride 5Mg
Hytrin
Tablet; Oral
NDA No: 19057 Approved: 08/07/87

Patent Date: 05/31/94
Exclusivity Date:
Exclusivity Code:
Patent Number: 4026894

Terazosin Hydrochloride 5Mg
Hytrin
Tablet; Oral
NDA No: 19057 Approved: 08/07/87

Patent Date: 09/05/95
Exclusivity Date:
Exclusivity Code:
Patent Number: 4112097

Terazosin Hydrochloride 5Mg
Hytrin
Tablet; Oral
NDA No: 19057 Approved: 08/07/87

Patent Date: 02/17/00
Exclusivity Date: 08/07/92
Exclusivity Code: NCE
Patent Number: 4251532

Adria Laboratories

Bentiromide 500Mg/7.5Ml
Chymex
Solution; Oral
NDA No: 18366 Approved: 12/29/83

Patent Date: 07/10/90
Exclusivity Date:
Exclusivity Code:
Patent Number: 3745212

Bentiromide 500Mg/7.5Ml
Chymex
Solution; Oral
NDA No: 18366 Approved: 12/29/83

Patent Date: 04/02/91
Exclusivity Date: 12/29/93
Exclusivity Code: NCE
Patent Number: 3801562

Alcon Laboratories

Apraclonidine Hydrochloride Eq 1% Base
Iopidine
Solution; Ophthalmic
NDA No: 19779 Approved: 12/31/87

Patent Date: 05/14/02
Exclusivity Date: 12/31/92
Exclusivity Code: NCE
Patent Number: 4517199

Betaxolol Hydrochloride Eq 0.5% Base
Betoptic
Solution; Ophthalmic
NDA No: 19270 Approved: 08/30/85

Patent Date: 01/19/99
Exclusivity Date:
Exclusivity Code:
Patent Number: 4311708

Betaxolol Hydrochloride Eq 0.5% Base
Betoptic
Solution; Ophthalmic
NDA No: 19270 Approved: 08/30/85

Patent Date: 08/03/99
Exclusivity Date:
Exclusivity Code:
Patent Number: 4342783

Betaxolol Hydrochloride Eq 0.5% Base
Betoptic
Solution; Ophthalmic
NDA No: 19270 Approved: 08/30/85

Patent Date: 07/31/99
Exclusivity Date: 08/30/90
Exclusivity Code: NCE
Patent Number: 4252984

Fluorometholone Acetate 0.1%
Flarex
Suspension; Ophthalmic
NDA No: 19079 Approved: 02/11/86

Patent Date:
Exclusivity Date: 02/11/89
Exclusivity Code: NE
Patent Number:

Suprofen 1%
Profenal
Solution; Ophthalmic
NDA No: 19387 Approved: 12/23/88

Patent Date: 07/12/96
Exclusivity Date: 12/23/91
Exclusivity Code: NDF
Patent Number: 4035376

Suprofen 1%
Profenal
Solution; Ophthalmic
NDA No: 19387 Approved: 12/23/88

Patent Date: 12/17/02
Exclusivity Date: 12/24/90
Exclusivity Code: NCE
Patent Number: 4559343

Allergan Pharmaceuticals

Dipivefrin Hydrochloride 0.1%
Propine
Solution; Ophthalmic
NDA No: 18239 Approved: 05/02/80

Patent Date: 05/07/91
Exclusivity Date:
Exclusivity Code:
Patent Number: 3809714

Dipivefrin Hydrochloride 0.1%
Propine
Solution; Ophthalmic
NDA No: 18239 Approved: 05/02/80

Patent Date: 10/01/91
Exclusivity Date:
Exclusivity Code:
Patent Number: 3839584

Flurbiprofen Sodium 0.03%
Ocufen
Solution; Ophthalmic
NDA No: 19404 Approved: 12/31/86

Patent Date: 08/28/90
Exclusivity Date: 12/31/91
Exclusivity Code: NCE
Patent Number: 3755427

Flurbiprofen Sodium 0.03%
Ocufen
Solution; Ophthalmic
NDA No: 19404 Approved: 12/31/86

Patent Date: 02/19/93
Exclusivity Date:
Exclusivity Code:
Patent Number: 3793457

1 Co.

Levobunolol Hydrochloride 0.5%
Betagan
Solution; Ophthalmic
NDA No: 19219 Approved: 12/19/85
Patent Date: 02/08/89
Exclusivity Date: 12/19/90
Exclusivity Code: NCE
Patent Number: 3641152

American Hoechst

Ciclopirox Olamine 1%
Loprox
Emulsion, Cream; Topical
NDA No: 18748 Approved: 12/30/82
Patent Date: 05/13/92
Exclusivity Date: 12/30/92
Exclusivity Code: NCE
Patent Number: 3883545

Ciclopirox Olamine 1%
Loprox
Lotion; Topical
NDA No: 19824 Approved: 12/30/88
Patent Date:
Exclusivity Date: 12/30/91
Exclusivity Code: NDF
Patent Number:

Ciclopirox Olamine 1%
Loprox
Lotion; Topical
NDA No: 19824 Approved: 12/30/88
Patent Date: 05/13/92
Exclusivity Date: 12/30/92
Exclusivity Code: NCE
Patent Number: 3883545

Glyburide 1.25Mg
Diabeta
Tablet; Oral
NDA No: 17532 Approved: 05/01/84
Patent Date: 04/21/92
Exclusivity Date:
Exclusivity Code:
Patent Number: 3507961

Glyburide 1.25Mg
Diabeta
Tablet; Oral
NDA No: 17532 Approved: 05/01/84
Patent Date: 04/21/92
Exclusivity Date: 05/01/94
Exclusivity Code: NCE
Patent Number: 3426067

Glyburide 1.25Mg
Diabeta
Tablet; Oral
NDA No: 17532 Approved: 05/01/84
Patent Date: 04/21/92
Exclusivity Date:
Exclusivity Code:
Patent Number: 3454635

Glyburide 1.25Mg
Diabeta
Tablet; Oral
NDA No: 17532 Approved: 05/01/84
Patent Date: 04/21/92
Exclusivity Date:
Exclusivity Code:
Patent Number: 3507954

Glyburide 1.25Mg
Diabeta
Tablet; Oral
NDA No: 17532 Approved: 05/01/84
Patent Date: 09/07/93
Exclusivity Date:
Exclusivity Code:
Patent Number: 4060634

Glyburide 2.5Mg		Patent Date:	04/21/92
Diabeta		Exclusivity Date:	
Tablet; Oral		Exclusivity Code:	
NDA No: 17532	Approved: 05/01/84	Patent Number:	3507961
Glyburide 2.5Mg		Patent Date:	04/21/92
Diabeta		Exclusivity Date:	05/01/94
Tablet; Oral		Exclusivity Code:	NCE
NDA No: 17532	Approved: 05/01/84	Patent Number:	3426067
Glyburide 2.5Mg		Patent Date:	04/21/92
Diabeta		Exclusivity Date:	
Tablet; Oral		Exclusivity Code:	
NDA No: 17532	Approved: 05/01/84	Patent Number:	3454635
Glyburide 2.5Mg		Patent Date:	04/21/92
Diabeta		Exclusivity Date:	
Tablet; Oral		Exclusivity Code:	
NDA No: 17532	Approved: 05/01/84	Patent Number:	3507954
Glyburide 2.5Mg		Patent Date:	09/07/93
Diabeta		Exclusivity Date:	
Tablet; Oral		Exclusivity Code:	
NDA No: 17532	Approved: 05/01/84	Patent Number:	4060634
Glyburide 5Mg		Patent Date:	04/21/92
Diabeta		Exclusivity Date:	
Tablet; Oral		Exclusivity Code:	
NDA No: 17532	Approved: 05/01/84	Patent Number:	3507961
Glyburide 5Mg		Patent Date:	04/21/92
Diabeta		Exclusivity Date:	05/01/94
Tablet; Oral		Exclusivity Code:	NCE
NDA No: 17532	Approved: 05/01/84	Patent Number:	3426067
Glyburide 5Mg		Patent Date:	04/21/92
Diabeta		Exclusivity Date:	
Tablet; Oral		Exclusivity Code:	
NDA No: 17532	Approved: 05/01/84	Patent Number:	3454635
Glyburide 5Mg		Patent Date:	04/21/92
Diabeta		Exclusivity Date:	
Tablet; Oral		Exclusivity Code:	
NDA No: 17532	Approved: 05/01/84	Patent Number:	3507954

1 Co.

Glyburide 5Mg
Diabeta
Tablet; Oral
NDA No: 17532 Approved: 05/01/84

Patent Date: 09/07/93
Exclusivity Date:
Exclusivity Code:
Patent Number: 4060634

Nomifensine Maleate 25Mg
Merital
Capsule; Oral
NDA No: 18224 Approved: 12/31/84

Patent Date:
Exclusivity Date: 12/31/89
Exclusivity Code: NCE
Patent Number:

Nomifensine Maleate 50Mg
Merital
Capsule; Oral
NDA No: 18224 Approved: 12/31/84

Patent Date:
Exclusivity Date: 12/31/89
Exclusivity Code: NCE
Patent Number:

Pentoxifylline 400Mg
Trental
Tablet, Sustained Action; Oral
NDA No: 18631 Approved: 08/30/84

Patent Date: 02/02/97
Exclusivity Date:
Exclusivity Code:
Patent Number: 4189469

Pentoxifylline 400Mg
Trental
Tablet, Sustained Action; Oral
NDA No: 18631 Approved: 08/30/84

Patent Date: 06/05/90
Exclusivity Date: 08/30/94
Exclusivity Code: NCE
Patent Number: 3737433

Protirelin 0.5Mg/Ml
Relefact Trh
Injection; Intravenous
NDA No: 18087 Approved: 07/18/78

Patent Date: 07/17/90
Exclusivity Date:
Exclusivity Code:
Patent Number: 3746697

Amersham

Indium In-111 Oxyquinoline 1Mci/Ml
Indium In-111 Oxyquinoline
Injectable; Intravenous
NDA No: 19044 Approved: 12/23/85

Patent Date: 06/15/99
Exclusivity Date: 12/23/90
Exclusivity Code: NCE
Patent Number: 4335095

Anaquest

Isoflurane 99.9%
Forane
Liquid; Inhalation
NDA No: 17624 Approved: 12/18/79

Patent Date: 01/24/93
Exclusivity Date:
Exclusivity Code:
Patent Number: 3535425

Isoflurane 99.9%
Forane
Liquid; Inhalation
NDA No: 17624 Approved: 12/18/79

Patent Date: 01/24/93
Exclusivity Date:
Exclusivity Code:
Patent Number: 3535388

Astra Pharmaceutical

Epinephrine 0.005Mg/Ml; Etidocaine Hydrochloride 0.5%
Duranest
Injection; Peridural
NDA No: 17751 Approved: 08/30/76
Patent Date: 05/21/91
Exclusivity Date:
Exclusivity Code:
Patent Number: 3812147

Epinephrine 0.005Mg/Ml; Etidocaine Hydrochloride 0.5%
Duranest
Injection; An,Infiltration
NDA No: 17751 Approved: 08/30/76
Patent Date: 05/21/91
Exclusivity Date:
Exclusivity Code:
Patent Number: 3812147

Epinephrine 0.005Mg/Ml; Etidocaine Hydrochloride 0.5%
Duranest
Injection; An,Infiltration
NDA No: 17751 Approved: 08/30/76
Patent Date: 01/21/92
Exclusivity Date:
Exclusivity Code:
Patent Number: 3862321

Epinephrine 0.005Mg/Ml; Etidocaine Hydrochloride 0.5%
Duranest
Injection; Peridural
NDA No: 17751 Approved: 08/30/76
Patent Date: 01/21/92
Exclusivity Date:
Exclusivity Code:
Patent Number: 3862321

Epinephrine Bitartrate 0.005Mg/Ml;
Etidocaine Hydrochloride 1%
Duranest
Injection; An,Infiltration
NDA No: 17751 Approved: 08/30/76
Patent Date: 05/21/91
Exclusivity Date:
Exclusivity Code:
Patent Number: 3812147

Epinephrine Bitartrate 0.005Mg/Ml;
Etidocaine Hydrochloride 1.5%
Duranest
Injection; Nerve Block
NDA No: 17751 Approved: 08/30/76
Patent Date: 01/21/92
Exclusivity Date:
Exclusivity Code:
Patent Number: 3862321

Epinephrine Bitartrate 0.005Mg/Ml;
Etidocaine Hydrochloride 1%
Duranest
Injection; An,Infiltration
NDA No: 17751 Approved: 08/30/76
Patent Date: 01/21/92
Exclusivity Date:
Exclusivity Code:
Patent Number: 3862321

Epinephrine Bitartrate 0.005Mg/Ml;
Etidocaine Hydrochloride 1%
Duranest
Injection; Epidural
NDA No: 17751 Approved: 08/30/76
Patent Date: 05/21/91
Exclusivity Date:
Exclusivity Code:
Patent Number: 3812147

1 Co.

Epinephrine Bitartrate 0.005Mg/Ml;
Etidocaine Hydrochloride 1%
Duranest
Injection; Epidural
NDA No: 17751 Approved: 08/30/76
Patent Date: 01/21/92
Exclusivity Date:
Exclusivity Code:
Patent Number: 3862321

Epinephrine Bitartrate 0.005Mg/Ml;
Etidocaine Hydrochloride 1.5%
Duranest
Injection; Nerve Block
NDA No: 17751 Approved: 08/30/76
Patent Date: 05/21/91
Exclusivity Date:
Exclusivity Code:
Patent Number: 3812147

Epinephrine Bitartrate 0.005Mg/Ml;
Etidocaine Hydrochloride 1.5%
Duranest
Injection; Epidural
NDA No: 17751 Approved: 08/30/76
Patent Date: 05/21/91
Exclusivity Date:
Exclusivity Code:
Patent Number: 3812147

Epinephrine Bitartrate 0.005Mg/Ml;
Etidocaine Hydrochloride 1.5%
Duranest
Injection; Epidural
NDA No: 17751 Approved: 08/30/76
Patent Date: 01/21/92
Exclusivity Date:
Exclusivity Code:
Patent Number: 3862321

Etidocaine Hydrochloride 0.5%
Duranest
Injection; An,Infiltration
NDA No: 17751 Approved: 08/30/76
Patent Date: 01/21/92
Exclusivity Date:
Exclusivity Code:
Patent Number: 3862321

Etidocaine Hydrochloride 0.5%
Duranest
Injection; Peridural
NDA No: 17751 Approved: 08/30/76
Patent Date: 01/21/92
Exclusivity Date:
Exclusivity Code:
Patent Number: 3862321

Etidocaine Hydrochloride 0.5%
Duranest
Injection; Peridural
NDA No: 17751 Approved: 08/30/76
Patent Date: 05/21/91
Exclusivity Date:
Exclusivity Code:
Patent Number: 3812147

Etidocaine Hydrochloride 0.5%
Duranest
Injection; An,Infiltration
NDA No: 17751 Approved: 08/30/76
Patent Date: 05/21/91
Exclusivity Date:
Exclusivity Code:
Patent Number: 3812147

Etidocaine Hydrochloride 1%
Duranest
Injection; Epidural
NDA No: 17751 Approved: 08/30/76
Patent Date: 05/21/91
Exclusivity Date:
Exclusivity Code:
Patent Number: 3812147

Etidocaine Hydrochloride 1%
Duranest
Injection; An,Infiltration
NDA No: 17751 Approved: 08/30/76
Patent Date: 01/21/92
Exclusivity Date:
Exclusivity Code:
Patent Number: 3862321

Etidocaine Hydrochloride 1%
Duranest
Injection; Epidural
NDA No: 17751 Approved: 08/30/76
Patent Date: 01/21/92
Exclusivity Date:
Exclusivity Code:
Patent Number: 3862321

Etidocaine Hydrochloride 1%
Duranest
Injection; An,Infiltration
NDA No: 17751 Approved: 08/30/76
Patent Date: 05/21/91
Exclusivity Date:
Exclusivity Code:
Patent Number: 3812147

Mesna 100Mg/Ml
Mesnex
Injection; Intravenous
NDA No: 19884 Approved: 12/30/88
Patent Date: 09/02/97
Exclusivity Date: 12/30/95
Exclusivity Code: ODE
Patent Number: 4220660

Mesna 100Mg/Ml
Mesnex
Injection; Intravenous
NDA No: 19884 Approved: 12/30/88
Patent Date:
Exclusivity Date: 12/30/93
Exclusivity Code: NCE
Patent Number:

Berlex Laboratories

Gadopentetate Dimeglumine 469.01Mg/Ml
Magnevist
Injection; Intravenous
NDA No: 19596 Approved: 06/02/88
Patent Date: 03/03/04
Exclusivity Date: 06/02/93
Exclusivity Code: NCE
Patent Number: 4647447

Boehringer Ingelheim

Chlorthalidone 15Mg
Thalitone
Tablet; Oral
NDA No: 19574 Approved: 12/20/88
Patent Date:
Exclusivity Date: 12/20/91
Exclusivity Code: NS
Patent Number:

Clonidine 0.1Mg/24Hr
Catapres-Tts-1
Film, Controlled Release; Percutaneous
NDA No: 18891 Approved: 10/10/84
Patent Date: 06/28/94
Exclusivity Date:
Exclusivity Code:
Patent Number: 4060084

Clonidine 0.1Mg/24Hr
Catapres-Tts-1
Film, Controlled Release; Percutaneous
NDA No: 18891 Approved: 10/10/84
Patent Date: 07/29/92
Exclusivity Date:
Exclusivity Code:
Patent Number: 3996934

1 Co.

Clonidine 0.1Mg/24Hr
Catapres-Tts-1
Film, Controlled Release; Percutaneous
NDA No: 18891 Approved: 10/10/84
Patent Date: 05/06/97
Exclusivity Date:
Exclusivity Code:
Patent Number: 4201211

Clonidine 0.1Mg/24Hr
Catapres-Tts-1
Film, Controlled Release; Percutaneous
NDA No: 18891 Approved: 10/10/84
Patent Date: 12/17/02
Exclusivity Date:
Exclusivity Code:
Patent Number: 4559222

Clonidine 0.2Mg/24Hr
Catapres-Tts-2
Film, Controlled Release; Percutaneous
NDA No: 18891 Approved: 10/10/84
Patent Date: 06/28/94
Exclusivity Date:
Exclusivity Code:
Patent Number: 4060084

Clonidine 0.2Mg/24Hr
Catapres-Tts-2
Film, Controlled Release; Percutaneous
NDA No: 18891 Approved: 10/10/84
Patent Date: 05/06/97
Exclusivity Date:
Exclusivity Code:
Patent Number: 4201211

Clonidine 0.2Mg/24Hr
Catapres-Tts-2
Film, Controlled Release; Percutaneous
NDA No: 18891 Approved: 10/10/84
Patent Date: 12/17/02
Exclusivity Date:
Exclusivity Code:
Patent Number: 4559222

Clonidine 0.2Mg/24Hr
Catapres-Tts-2
Film, Controlled Release; Percutaneous
NDA No: 18891 Approved: 10/10/84
Patent Date: 07/29/92
Exclusivity Date:
Exclusivity Code:
Patent Number: 3996934

Clonidine 0.3Mg/24Hr
Catapres-Tts-3
Film, Controlled Release; Percutaneous
NDA No: 18891 Approved: 10/10/84
Patent Date: 07/29/92
Exclusivity Date:
Exclusivity Code:
Patent Number: 3996934

Clonidine 0.3Mg/24Hr
Catapres-Tts-3
Film, Controlled Release; Percutaneous
NDA No: 18891 Approved: 10/10/84
Patent Date: 05/06/97
Exclusivity Date:
Exclusivity Code:
Patent Number: 4201211

Clonidine 0.3Mg/24Hr
Catapres-Tts-3
Film, Controlled Release; Percutaneous
NDA No: 18891 Approved: 10/10/84
Patent Date: 12/17/02
Exclusivity Date:
Exclusivity Code:
Patent Number: 4559222